Phase 1b/2 to Evaluate the Safety, Tolerability, and Efficacy of TXN10128 in Combination With TOPO-I Inhibitor-based Therapies (Irinotecan or TROP2 ADC) in Advanced or Metastatic EGFR Mutated NSCLC

Recruiting

Plain-English translation of NCT07933055 on ClinicalTrials.gov ↗ · Source last updated November 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

Trial locations(8 sites)

South Korea

Ajou University Hospital, Gyeonggi-do

Seoul University Bundang Hospital, Gyeonggi-do

The Catholic University of Korea, ST. Vincent's Hospital, Gyeonggi-do

Gachon University Gil Medical Center, Incheon

HanYang Univ. Hospital, Seoul